Argentina's Nicotine Dilemma: A Pouch of Hope or a Health Risk?

BUENOS AIRES, Argentina – March 06, 2026 – As the world prepares to mark International Women’s Day, a stark public health contrast is playing out between Sweden and Argentina, centered on a small, tobacco-free product: the nicotine pouch. A new report is urging Argentinian policymakers to look north, where these pouches are credited with a dramatic drop in female smoking rates, while here in Argentina, a regulatory vacuum leaves millions of women with few viable alternatives to combustible cigarettes.

The report, titled Empowerment in a Pouch, released by the advocacy group Smoke Free Sweden, argues that Argentina's failure to regulate oral nicotine pouches is depriving women of a powerful tool to quit smoking. With an estimated 18% of adult women in Argentina projected to be daily smokers in 2025, the stakes are incredibly high, representing millions of lives exposed to preventable cancers, cardiovascular diseases, and respiratory illnesses.

“Sweden’s experience shows what happens when women are given realistic alternatives to smoking,” said Professor Marewa Glover, a behavioural scientist and co-author of the report. “When safer options are accessible and clearly regulated, women quit at scale. When alternatives are banned or left in limbo, cigarettes remain the default.”

Sweden's Smoke-Free Blueprint

Sweden is on the verge of a historic public health achievement: becoming the first country in the world to be officially classified as “smoke-free,” with a daily smoking rate below 5%. The new report posits that the widespread availability of smoke-free alternatives, particularly nicotine pouches, has been a primary driver of this success, especially among women.

Since nicotine pouches became widely available in Sweden around 2016, the data is compelling. The country has seen female smoking rates plummet by nearly 50%, a decline that is reportedly six times faster than the average across Europe. Research accompanying the report, which included surveys and focus groups, found that Swedish women ranked nicotine pouches as the most effective quitting aid, outperforming both vaping products and traditional nicotine replacement therapies like gums and patches.

Participants cited the pouches' discretion, convenience, and variety of flavors as key factors in their success. This has led to a threefold increase in quit rates among women, putting the nation on a fast track to achieving its smoke-free goal. The Swedish model, as presented by its proponents, is one of pragmatic harm reduction: providing smokers with less harmful ways to consume nicotine, thereby weaning them off the deadly combustion of traditional cigarettes.

Argentina's Regulatory Deadlock

In stark contrast, Argentina's tobacco control landscape is a complex web of prohibitions and a lack of specific regulation. While combustible cigarettes are legal and widely available, the government has taken a hardline stance against alternatives. Vaping products have been banned since 2011, and a ban on heated tobacco products followed in 2023.

Nicotine pouches, however, exist in a legal gray area. With no specific laws governing their sale or marketing, they are increasingly available online and in kiosks, often sold without the graphic health warnings required for other tobacco-related products. Major international tobacco companies like British American Tobacco and Philip Morris International have already introduced their respective brands, VELO and ZYN, into this unregulated market.

This situation has alarmed local public health organizations. Groups like the Argentine Anti-Tobacco Union (UATA) argue that these products, due to their high nicotine content and association with tobacco brands, should fall under the existing national tobacco control law. They are pushing for stricter oversight, concerned about the products' addictive potential and appeal to young people, while cigarettes remain the most accessible nicotine product on the market.

A Global Divide on Harm Reduction

The policy chasm between Sweden and Argentina reflects a broader, fiercely contested global debate on tobacco harm reduction. There is no international consensus on how to handle novel nicotine products. In the United States, the Food and Drug Administration (FDA) recently authorized the marketing of some ZYN nicotine pouches, concluding they are lower-risk than smoking but stressing they are not risk-free and remain addictive.

Across Europe, the approach is fragmented. While the United Kingdom has generally embraced harm reduction, other nations like France, the Netherlands, and Belgium have moved to restrict or ban nicotine pouches. The European Commission itself is contemplating EU-wide restrictions, which could challenge the very model that has proven successful in Sweden.

Meanwhile, the World Health Organization (WHO) has urged caution, recommending bans on flavored nicotine products to prevent youth uptake. This perspective prioritizes preventing a new generation of nicotine users over providing current smokers with potentially less harmful alternatives. Argentina's current de facto policy—banning new products while allowing cigarettes—aligns more closely with a prohibitionist stance, a path that critics say has failed to significantly lower its high smoking rates.

The Science of the Pouch: Panacea or Peril?

At the heart of the policy debate is the scientific evidence, which remains complex and incomplete. Proponents of harm reduction point to clear data showing that nicotine pouches, which contain no tobacco and do not involve combustion, expose users to significantly lower levels of the harmful toxicants and carcinogens found in cigarette smoke.

However, the independent scientific community urges caution. A recent comprehensive review from the Cochrane Database, a respected source for evidence-based medicine, found that while pouches may reduce toxicant exposure, the evidence that they actually help people quit smoking is currently inconclusive. The review highlighted a critical lack of large, long-term, independent studies.

Concerns also persist about the high addiction potential of nicotine itself. High-dose pouches can deliver nicotine to the bloodstream as rapidly as cigarettes, raising fears of creating or sustaining dependence. Furthermore, potential long-term cardiovascular and oral health risks from sustained nicotine use are not yet fully understood. This leaves policymakers with a difficult choice, balancing the known devastation of smoking against the unknown long-term risks of a new product.

As Argentina considers its next steps, the warning from the Empowerment in a Pouch report hangs in the air. “Clear, risk-based regulation of smoke-free products could reduce smoking-related disease,” stated Dr. Delon Human, a co-author and former Secretary-General of the World Medical Association. “Continuing uncertainty risks locking women into the most harmful form of nicotine use.” The decision Argentina makes will be a critical test of its public health strategy, with the health of millions of its citizens hanging in the balance.